• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

米替福新（Impavido）：第一种治疗利什曼病的口服药物。

Miltefosine (Impavido): the first oral treatment against leishmaniasis.

作者信息

Sindermann H, Croft S L, Engel K R, Bommer W, Eibl H J, Unger C, Engel J

机构信息

Zentaris AG, Weismüllerstrasse 45, 60314 Frankfurt am Main, Germany.

出版信息

Med Microbiol Immunol. 2004 Nov;193(4):173-80. doi: 10.1007/s00430-003-0201-2. Epub 2003 Sep 26.

DOI:10.1007/s00430-003-0201-2
PMID:14513375
Abstract

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

摘要

米替福新是一种新型抗利什曼原虫药物，在体外和体内模型中均具有显著的选择性。已证实其对内脏利什曼病的治疗具有临床疗效，与目前推荐的需要肠胃外给药的抗利什曼原虫药物相比，口服给药具有优势。米替福新对标准锑剂治疗耐药的患者也有较高的治愈率。

相似文献

1
Miltefosine (Impavido): the first oral treatment against leishmaniasis.米替福新（Impavido）：第一种治疗利什曼病的口服药物。
Med Microbiol Immunol. 2004 Nov;193(4):173-80. doi: 10.1007/s00430-003-0201-2. Epub 2003 Sep 26.
2
[Leishmaniasis--oral treatment with hexadecylphosphocholine].[利什曼病——十六烷基磷酸胆碱的口服治疗]
Wien Klin Wochenschr. 2004;116 Suppl 4:24-9.
3
Miltefosine (Impavido) for leishmaniasis.米替福新（Impavido）用于治疗利什曼病。
Med Lett Drugs Ther. 2014 Sep 15;56(1451):89-90.
4
Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.儿童内脏利什曼病的口服米替福新治疗：简要综述
Braz J Infect Dis. 2008 Feb;12(1):2-4. doi: 10.1590/s1413-86702008000100002.
5
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.米替福新：一种治疗利什曼病的药理学和治疗功效的综述。
J Antimicrob Chemother. 2012 Nov;67(11):2576-97. doi: 10.1093/jac/dks275. Epub 2012 Jul 24.
6
Treatment of leishmaniasis with miltefosine: 2008 status.用米替福新治疗利什曼病：2008年现状。
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209.
7
Miltefosine and cutaneous leishmaniasis.米替福新与皮肤利什曼病。
Curr Opin Infect Dis. 2012 Apr;25(2):141-4. doi: 10.1097/QCO.0b013e3283509cac.
8
Miltefosine for new world cutaneous leishmaniasis.米替福新治疗新大陆皮肤利什曼病。
Clin Infect Dis. 2004 May 1;38(9):1266-72. doi: 10.1086/383321. Epub 2004 Apr 9.
9
Miltefosine: oral treatment of leishmaniasis.米替福新：利什曼病的口服治疗
Expert Rev Anti Infect Ther. 2006 Apr;4(2):177-85. doi: 10.1586/14787210.4.2.177.
10
Miltefosine--the long-awaited therapy for visceral leishmaniasis?米替福新——内脏利什曼病期待已久的治疗方法？
N Engl J Med. 1999 Dec 9;341(24):1840-2. doi: 10.1056/NEJM199912093412411.

引用本文的文献

1
Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.皮肤利什曼病的治疗及物种特异性反应的见解：一篇叙述性综述
Infect Dis Ther. 2022 Apr;11(2):695-711. doi: 10.1007/s40121-022-00602-2. Epub 2022 Feb 22.
2
Total synthesis of (+)-spiroindimicin A and congeners unveils their antiparasitic activity.(+)-螺旋吲哚霉素A及其类似物的全合成揭示了它们的抗寄生虫活性。
Chem Sci. 2021 Jun 30;12(30):10388-10394. doi: 10.1039/d1sc02838c. eCollection 2021 Aug 4.
3
A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.

本文引用的文献

1
[INCREASE IN THE PHAGOCYTOSIS OF PERITONEAL MACROPHAGES BY LYSOLECITHIN].
Z Naturforsch B. 1964 Dec;19:1118-20.
2
Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.口服米替福新治疗轻度至中度印度内脏利什曼病患儿。
Pediatr Infect Dis J. 2003 May;22(5):434-8. doi: 10.1097/01.inf.0000066877.72624.cb.
3
Oral miltefosine for Indian visceral leishmaniasis.口服米替福新治疗印度内脏利什曼病。
N Engl J Med. 2002 Nov 28;347(22):1739-46. doi: 10.1056/NEJMoa021556.
一项随机临床试验：米替福新联合五价锑剂与己酮可可碱治疗美洲皮肤利什曼病。
Front Cell Infect Microbiol. 2021 Jul 1;11:700323. doi: 10.3389/fcimb.2021.700323. eCollection 2021.
4
Computational approaches for drug discovery against trypanosomatid-caused diseases.计算方法在针对利什曼原虫和锥虫引起的疾病的药物发现中的应用。
Parasitology. 2020 May;147(6):611-633. doi: 10.1017/S0031182020000207. Epub 2020 Feb 12.
5
Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges.纳米材料在利什曼病中的应用：聚焦最新进展与挑战
Nanomaterials (Basel). 2019 Dec 9;9(12):1749. doi: 10.3390/nano9121749.
6
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.米替福新通过免疫调节在利什曼病中宿主介导活性的系统评价。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.02507-18. Print 2019 Jul.
7
Simple and efficient synthesis of 5'-aryl-5'-deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities.通过叠氮化物-炔烃点击反应简单高效地合成5'-芳基-5'-脱氧鸟苷类似物及其抗利什曼原虫活性。
Mol Divers. 2016 May;20(2):507-19. doi: 10.1007/s11030-015-9652-9. Epub 2016 Jan 11.
8
Advances in Development of New Treatment for Leishmaniasis.利什曼病新疗法的研发进展
Biomed Res Int. 2015;2015:815023. doi: 10.1155/2015/815023. Epub 2015 May 11.
9
Crovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and Leishmania.克罗维林，一种富含半胱氨酸的蛇毒分泌蛋白（CRISP），对锥虫和利什曼原虫具有潜在活性。
PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3252. doi: 10.1371/journal.pntd.0003252. eCollection 2014 Oct.
10
Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms.米尔泰菌素诱导的成年曼氏血吸虫 BH 株虫体表膜损伤的超微结构分析。
Parasitol Res. 2012 Jun;110(6):2465-73. doi: 10.1007/s00436-011-2786-5. Epub 2012 Jan 4.
4
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.利什曼原虫对十六烷基磷酸胆碱（米替福新）、ET-18-OCH(3)（依地福新）和两性霉素B的敏感性。
Acta Trop. 2002 Feb;81(2):151-7. doi: 10.1016/s0001-706x(01)00197-8.
5
Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.使用口服药物米替福新治疗美洲皮肤利什曼病。
Clin Infect Dis. 2001 Oct 1;33(7):E57-61. doi: 10.1086/322689. Epub 2001 Sep 5.
6
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.十六烷基磷酸胆碱（米替福新）、两性霉素B脂质体和葡萄糖酸锑钠（喷他脒）对免疫缺陷型重度联合免疫缺陷（scid）小鼠体内杜氏利什曼原虫的活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
7
Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole.抗增殖溶血磷脂类似物对原生动物寄生虫克氏锥虫的作用机制：固醇生物合成抑制剂酮康唑对体外活性的增强作用
J Antimicrob Chemother. 2001 May;47(5):537-46. doi: 10.1093/jac/47.5.537.
8
Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.醚脂（烷基磷脂）代谢及醚脂类似物在利什曼原虫中的作用机制
Mol Biochem Parasitol. 2000 Nov;111(1):1-14. doi: 10.1016/s0166-6851(00)00278-4.
9
Short-course of oral miltefosine for treatment of visceral leishmaniasis.口服米替福新短疗程治疗内脏利什曼病
Clin Infect Dis. 2000 Oct;31(4):1110-3. doi: 10.1086/318122.
10
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.口服米替福新对T细胞缺陷小鼠实验性内脏利什曼病治疗后复发的抑制作用
Antimicrob Agents Chemother. 2000 Nov;44(11):3235-6. doi: 10.1128/AAC.44.11.3235-3236.2000.